ARCHIVES

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Clinical Trial System Inefficient, UPCI Director Tells Senate

June 7, 2002

NIH selects nine scientists for Pioneer Awards.

October 1, 2004

In Brief: Richard Fisher Named Fox Chase President and CEO

August 2, 2013

AACR Unanimously Backs Tough Antismoking Measure

May 18, 1984

Also Coltman to step down as SWOG chairman, Baker is chairman-elect.

July 25, 2003

ODAC Reviews Post-Marketing Studies for Eight Indications

March 21, 2003